{"symbol": "KALV", "name": "KalVista Pharmaceuticals", "next_earnings_utc": 1591702200, "next_earnings_period_start_date_utc": 1580428800, "next_earnings_period_end_date_utc": 1588204800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q4", "next_earnings_year": 2020, "next_earnings_quarter": 4, "next_earnings_revenue_num_analysts": null, "next_earnings_revenue_consensus": 1670430.0, "next_earnings_eps_num_analysts": null, "next_earnings_eps_consensus": -0.598, "eps_up_revisions": 1, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 4, "total_analysts": 7, "analysts_sell": 0, "analysts_buy": 5, "analysts_outperform": 2, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "kalvista.com", "year_founded": null, "street_address": "55 Cambridge Parkway", "city": "Cambridge", "state": "MA", "zipcode": "02142", "country": "United States", "phone_number": "857-999-0075", "short_description": "KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors.", "long_description": "KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company\u00e2\u20ac\u2122s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE; and KVD824, an oral plasma kallikrein inhibitor that is in Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 200762988, "total_enterprise": 121710988, "number_of_employees": 45, "outstanding_shares": 17845599, "eps": -1.766289, "diluted_eps": -1.766289, "earnings_from_cont_operations": -31058000, "gross_profit": -30056000, "cash": 80570000, "total_debt": 1518000, "total_revenue": 11792000, "cash_from_operations": -42709000, "net_income": -31058000, "ebitda": -42332000, "year_low_stock_price": 5.61, "year_high_stock_price": 24.05, "seekingalpha_follower_count": 2220, "image_url": "https://raw.githubusercontent.com/earnbros/earnbros.github.io/master/api/images/companies/KALV.png"}